This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ANIK or TECH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ANIK vs. TECH: Which Stock Is the Better Value Option?
New Strong Sell Stocks for November 20th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Techne (TECH) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Techne (TECH) delivered earnings and revenue surprises of 1.03% and 0.58%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Techne (TECH) Q1 Earnings Preview: How Are Events Shaping Up?
by Zacks Equity Research
Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bio-Techne Partners Micropoint Bioscience, Expands in China
by Zacks Equity Research
Bio-Techne (TECH) believes that its Chinese collaboration is a strategic fit as it will solidify the integration of microfluidic technology for more apt POC diagnostic tools for precision medicine.
New Strong Sell Stocks for October 3rd
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
3 Reasons Momentum Stock Investors Will Love Bio-Techne (TECH)
by Zacks Equity Research
Momentum stock investors will love Bio-Techne (TECH) seeing its favorable price performance both in short and long term.
The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Bio-Techne, Exelixis, Paratek and Bioverativ
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Bio-Techne, Exelixis, Paratek and Bioverativ
Will Core Segmental Growth Aid Stryker (SYK) in Q4 Earnings?
by Zacks Equity Research
Stryker's (SYK) robust fundamentals and broad product scale are likely to drive performance in the Q4. However, the company faces product-recall issues.
Fancy Biotech Stocks on Buyout Buzz? 5 Top Picks
by Tirthankar Chakraborty
More deals are expected to be signed in the biotech space, now that the tax reform bill allows companies to repatriate cash pilling up overseas.
Top Ranked Momentum Stocks to Buy for January 23rd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, January 23rd:
Is a Surprise Coming for Bio-Techne (TECH) This Earnings Season?
by Zacks Equity Research
Bio-Techne (TECH) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Bio-Techne's New Simple Plex Cartridge Boosts Protein Segment
by Zacks Equity Research
Bio-Techne (TECH) introduces a multi-analyte cartridge format for the Ella immunoassay platform. The cartridge provides more accurate results at a lower cost.
Luminex (LMNX) Banks on FDA Approvals & Portfolio Strength
by Zacks Equity Research
Luminex Corp (LMNX) is focusing on augmenting its portfolio strength through new FDA approvals.
Bio-Techne (TECH) Beats Earnings, Revenue Estimates in Q4
by Zacks Equity Research
Bio-Techne (TECH) rides high on strength in all three segments in Q4. Also, the company is focusing on product innovation through research and development.
Can Stratasys (SSYS) Pull a Surprise This Earnings Season?
by Zacks Equity Research
Launching innovative products, strategic partnerships and acquisitions, along with improving cost efficiencies are likely to are likely to strengthen Stratasys' (SSYS) Q2 results.
Should You Buy Bio-Techne (TECH) Ahead of Earnings?
by Zacks Equity Research
Bio-Techne (TECH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
CyberArk Software (CYBR) Q2 Earnings: Likely to Disappoint?
by Zacks Equity Research
CyberArk Software's (CYBR) slowdown in revenue growth, competition from peers and uncertain macroeconomic environment are likely to remain headwinds in Q2.
4 Sell-Ranked Drug Stocks Investors Should Avoid Ahead of Earnings
by Arpita Dutt
Here is a look at four Sell-Ranked drug stocks with negative earnings ESP that should be avoided ahead of earnings.
Implied Volatility Surging for Bio-Techne (TECH) Stock Options
by Zacks Equity Research
Options traders are pricing in a big move for Bio-Techne (TECH) shares as it has huge implied volatility.
Drug Stocks Reporting Earnings on Feb 7: GILD, MNK & More
by Zacks Equity Research
Earnings growth turned positive in the last quarter and things are surely looking up as we stand in the middle of the earnings season.